Cargando…

Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali

To determine a demographic overview of orthopoxvirus seroprevalence, we tested blood samples collected during 2003–2019 from France (n = 4,876), Bolivia (n = 601), Laos (n = 657), and Mali (n = 255) for neutralizing antibodies against vaccinia virus. In addition, we tested 4,448 of the 4,876 samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Luciani, Léa, Lapidus, Nathanaël, Amroun, Abdennour, Falchi, Alessandra, Souksakhone, Chanthala, Mayxay, Mayfong, Dubot-Pérès, Audrey, Villarroel, Paola Mariela Saba, Diarra, Issa, Koita, Ousmane, Gallian, Pierre, de Lamballerie, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707606/
https://www.ncbi.nlm.nih.gov/pubmed/36343384
http://dx.doi.org/10.3201/eid2812.221136
_version_ 1784840737631764480
author Luciani, Léa
Lapidus, Nathanaël
Amroun, Abdennour
Falchi, Alessandra
Souksakhone, Chanthala
Mayxay, Mayfong
Dubot-Pérès, Audrey
Villarroel, Paola Mariela Saba
Diarra, Issa
Koita, Ousmane
Gallian, Pierre
de Lamballerie, Xavier
author_facet Luciani, Léa
Lapidus, Nathanaël
Amroun, Abdennour
Falchi, Alessandra
Souksakhone, Chanthala
Mayxay, Mayfong
Dubot-Pérès, Audrey
Villarroel, Paola Mariela Saba
Diarra, Issa
Koita, Ousmane
Gallian, Pierre
de Lamballerie, Xavier
author_sort Luciani, Léa
collection PubMed
description To determine a demographic overview of orthopoxvirus seroprevalence, we tested blood samples collected during 2003–2019 from France (n = 4,876), Bolivia (n = 601), Laos (n = 657), and Mali (n = 255) for neutralizing antibodies against vaccinia virus. In addition, we tested 4,448 of the 4,876 samples from France for neutralizing antibodies against cowpox virus. We confirmed extensive cross-immunity between the 2 viruses. Seroprevalence of antibodies was <1% in Bolivia, <5% in Laos, and 17.25% in Mali. In France, we found low prevalence of neutralizing antibodies in persons who were unvaccinated and vaccinated for smallpox, suggesting immunosenescence occurred in vaccinated persons, and smallpox vaccination compliance declined before the end of compulsory vaccination. Our results suggest that populations in Europe, Africa, Asia, and South America are susceptible to orthopoxvirus infections, which might have precipitated the emergence of orthopoxvirus infections such as the 2022 spread of monkeypox in Europe.
format Online
Article
Text
id pubmed-9707606
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-97076062022-12-09 Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali Luciani, Léa Lapidus, Nathanaël Amroun, Abdennour Falchi, Alessandra Souksakhone, Chanthala Mayxay, Mayfong Dubot-Pérès, Audrey Villarroel, Paola Mariela Saba Diarra, Issa Koita, Ousmane Gallian, Pierre de Lamballerie, Xavier Emerg Infect Dis Research To determine a demographic overview of orthopoxvirus seroprevalence, we tested blood samples collected during 2003–2019 from France (n = 4,876), Bolivia (n = 601), Laos (n = 657), and Mali (n = 255) for neutralizing antibodies against vaccinia virus. In addition, we tested 4,448 of the 4,876 samples from France for neutralizing antibodies against cowpox virus. We confirmed extensive cross-immunity between the 2 viruses. Seroprevalence of antibodies was <1% in Bolivia, <5% in Laos, and 17.25% in Mali. In France, we found low prevalence of neutralizing antibodies in persons who were unvaccinated and vaccinated for smallpox, suggesting immunosenescence occurred in vaccinated persons, and smallpox vaccination compliance declined before the end of compulsory vaccination. Our results suggest that populations in Europe, Africa, Asia, and South America are susceptible to orthopoxvirus infections, which might have precipitated the emergence of orthopoxvirus infections such as the 2022 spread of monkeypox in Europe. Centers for Disease Control and Prevention 2022-12 /pmc/articles/PMC9707606/ /pubmed/36343384 http://dx.doi.org/10.3201/eid2812.221136 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Luciani, Léa
Lapidus, Nathanaël
Amroun, Abdennour
Falchi, Alessandra
Souksakhone, Chanthala
Mayxay, Mayfong
Dubot-Pérès, Audrey
Villarroel, Paola Mariela Saba
Diarra, Issa
Koita, Ousmane
Gallian, Pierre
de Lamballerie, Xavier
Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali
title Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali
title_full Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali
title_fullStr Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali
title_full_unstemmed Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali
title_short Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali
title_sort orthopoxvirus seroprevalence and infection susceptibility in france, bolivia, laos, and mali
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707606/
https://www.ncbi.nlm.nih.gov/pubmed/36343384
http://dx.doi.org/10.3201/eid2812.221136
work_keys_str_mv AT lucianilea orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT lapidusnathanael orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT amrounabdennour orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT falchialessandra orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT souksakhonechanthala orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT mayxaymayfong orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT dubotperesaudrey orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT villarroelpaolamarielasaba orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT diarraissa orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT koitaousmane orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT gallianpierre orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali
AT delamballeriexavier orthopoxvirusseroprevalenceandinfectionsusceptibilityinfrancebolivialaosandmali